Ingrid Louw

Nov 1, 2024 | jrheum.org | Hermine I Brunner |Cesar Pacheco-Tena |Ingrid Louw |Gabriel Vega-Cornejo

RESULTSParticipant disposition and baseline characteristics. Of the 127 participants included in the GO-VIVA main study primary analysis set,7 112/127 (88.2%) continued into the LTE, 71/127 (55.9%) completed IV golimumab dosing at week 244, and 69/127 (54.3%) completed follow-up at week 252 (Figure 1). AEs were the most common reason for discontinuation through week 252, accounting for 24 of the 127 (18.9%) LTE participants.

Aug 8, 2024 | jrheum.org | Hermine I Brunner |Cesar Pacheco-Tena |Ingrid Louw |Gabriel Vega-Cornejo

Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label, Phase III Study Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S. Gottlieb, Deborah M. Levy, C.

Jul 26, 2024 | jrheum.org | Hermine I Brunner |Cesar Pacheco-Tena |Ingrid Louw |Gabriel Vega-Cornejo

Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 Study Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S. Gottlieb, Deborah M. Levy, C.

Aug 17, 2023 | acrjournals.onlinelibrary.wiley.com | Hermine I Brunner |Nikolay Tzaribachev |Ingrid Louw |Inmaculada Calvo Penades

INTRODUCTION Juvenile idiopathic arthritis (JIA) is the term used to describe a group of noninfectious inflammatory conditions of unknown etiology with onset prior to age 16 years resulting in chronic arthritis for a minimum duration of 6 weeks (1, 2). JIA may be associated with extraarticular features such as uveitis, fever, and rashes (1, 2).

May 24, 2023 | onlinelibrary.wiley.com | Hermine I Brunner |Nikolay Tzaribachev |Ingrid Louw |Inmaculada Calvo Penades

Brief Report This study was supported by Bristol Myers Squibb. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/acr.25156.